Savings are vs. buying the same number of pouches at $64.95 each, the single-pouch price from Dec 1, 2026. 30% applies only to the first 8-pouch subscription shipment ($363.72 vs. 8 × $64.95); other options save 13%–25%. Later shipments renew at the regular subscription price.
Ends Mon Nov 30, 11:59 PM ET (8:59 PM PT).
HealthspanX / Publication archive
Explore individual publications and their study records. Read the source, the findings and the limits together.
Early human intervention / 2022
A small uncontrolled study found that one intravenous NMN dose raised blood NAD+ and lowered triglycerides over five hours, with no acute abnormalities detected.
Cureus
Read study recordNarrative review / 2024
Narrative review of NMN metabolism, uptake, gut microbiome effects, measurement challenges, and person-to-person variability in clinical findings.
Metabolites
Read study recordNarrative review / 2022
Narrative review of NMN anti-aging promises and safety concerns, emphasizing strong preclinical interest but sparse human efficacy and long-term safety evidence.
Journal of Advanced Research
Read study recordHuman randomized trial / 2023
Twelve-week trial in 36 middle-aged adults: serum nicotinamide increased, while the overall arterial-stiffness difference versus placebo was not significant.
Scientific Reports
Read study recordHuman randomized trial / 2022
Twelve-week four-group trial in 108 older adults: no significant sleep-quality interaction; drowsiness and sit-to-stand signals were accompanied by placebo improvements.
Nutrients
Read study recordHuman randomized trial / 2023
Two-week RCT in 32 adults aged 55–80 showing pharmaceutical-grade NMN (MIB-626) at 1,000 mg once or twice daily raised blood NAD⁺ substantially versus placebo with a safety profile matching placebo.
The Journals of Gerontology: Series A, Biological Sciences and Medical Sciences
Read study recordEarly human intervention / 2020
Single-dose study in 10 healthy men reporting no clinically significant acute changes over five hours and dose-related increases in downstream nicotinamide metabolites.
Endocrine Journal
Read study recordEarly human intervention / 2020
Single-dose study in 10 healthy men reporting no clinically significant acute changes over five hours and dose-related increases in downstream nicotinamide metabolites.
Endocrine Journal
Read study recordHuman randomized trial / 2021
Six-week, four-arm RCT (placebo / 300 / 600 / 1200 mg/day) in 48 amateur runners on ventilatory-threshold and aerobic-capacity measures.
Journal of the International Society of Sports Nutrition
Read study recordNarrative review / 2024
Narrative review of mainly preclinical ocular NMN studies; no human intervention evidence establishes prevention or treatment of ocular disease.
Graefe's Archive for Clinical and Experimental Ophthalmology
Read study recordCellular and structural study / 2022
Cryo-EM structural study resolving how NMN activates SARM1, the enzyme that drives axon degeneration when nerve injury depletes NMNAT2. Uses a nanobody to trap the active state.
Nature Communications
Read study recordPreclinical mechanistic study / 2015
Preclinical injury-model study linking local NMN accumulation after NMNAT2 loss with axon degeneration; not evidence about routine oral NMN use in people.
Cell Death & Differentiation
Read study recordThe Evidence Center brings study design, findings and limitations into the same view.
